CP 73850 structure
|
Common Name | CP 73850 | ||
---|---|---|---|---|
CAS Number | 110703-94-1 | Molecular Weight | 419.37700 | |
Density | 1.58g/cm3 | Boiling Point | 598.7ºC at 760mmHg | |
Molecular Formula | C19H12F3N3O3S | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | 315.9ºC | |
Symbol |
GHS06 |
Signal Word | Danger |
Use of CP 73850Zopolrestat (CP73850) is a potent, orally active aldose reductase (AR) inhibitor with an IC50 of 3.1 nM. Zopolrestat is used for the research of diabetic complications[1]. |
Name | Zopolrestat |
---|---|
Synonym | More Synonyms |
Description | Zopolrestat (CP73850) is a potent, orally active aldose reductase (AR) inhibitor with an IC50 of 3.1 nM. Zopolrestat is used for the research of diabetic complications[1]. |
---|---|
Related Catalog | |
In Vitro | Zopolrestat is a potent inhibitor of the reduction of both glyceraldehyde and glucose by the human and rat enzymes[1]. |
In Vivo | Zopolrestat (2.5 mg/kg-50 mg/kg; p.o.; once-a-day for 5 days) and left untreated for 7 days) prevents accumulation of sorbitol in the kidney cortex of diabetic rats and normalize elevated renal blood flow in galactosemic rats[1]. Animal Model: Male Sprague-Dawley rats (made diabetic by iv injection of streptozotocin)[1]. Dosage: 2.5 mg/kg-50 mg/kg Administration: P.o.; once-a-day for 5 days Result: Its ED50s in reversing already elevated sorbitol accumulation in rat sciatic nerve, retina, and lens in a chronic test were 1.9, 17.6, and 18.4 mg/kg, respectively. |
References |
Density | 1.58g/cm3 |
---|---|
Boiling Point | 598.7ºC at 760mmHg |
Molecular Formula | C19H12F3N3O3S |
Molecular Weight | 419.37700 |
Flash Point | 315.9ºC |
Exact Mass | 419.05500 |
PSA | 113.32000 |
LogP | 3.70040 |
Vapour Pressure | 3.5E-15mmHg at 25°C |
Index of Refraction | 1.683 |
Symbol |
GHS06 |
---|---|
Signal Word | Danger |
Hazard Statements | H301-H413 |
Precautionary Statements | P301 + P310 |
Hazard Codes | T+ |
RIDADR | UN 2811 6.1 / PGIII |
Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.
Eur. J. Pharmacol. 584 , 213-221, (2008) AKR1B10 is an aldose reductase (AR) homologue overexpressed in liver cancer and various forms of that enzyme in carcinomas catalyze the reduction of anticancer drugs, potential cytostatic drug, and dl... |
|
Mediation of aldose reductase in lipopolysaccharide-induced inflammatory signals in mouse peritoneal macrophages.
Cytokine 36(3-4) , 115-22, (2006) Aldose reductase (AR; AKR1B1) a member of aldo-keto reductase super family, that we had shown earlier mediates cytotoxic signals induced by high glucose, cytokines and growth factors, also mediates th... |
|
Endotoxin causes pulmonary hypertension by upregulating smooth muscle endothelin type-B receptors: role of aldose reductase.
Shock 30(2) , 189-96, (2008) Endothelin-1 (ET-1), a potent vasoconstrictor and mitogen, is upregulated in pulmonary tissue during endotoxemia and contributes markedly to endotoxin-induced pulmonary hypertension. It is, however, u... |
2-[4-oxo-3-[[5-(trifluoromethyl)-1,3-benzothiazol-2-yl]methyl]phthalazin-1-yl]acetic acid |